Multiple Myeloma: International Myeloma Foundation : • webcasts   : webcasts from medical meetings : Dr. Zonder - ASH 2008 - Phase I Study of Elotuzumab (HuLuc63) in Phase I Study of Elotuzumab (HuLuc63) in Relapsed/Refractory Multiple Myeloma

back

Dr. Zonder - ASH 2008 - Phase I Study of Elotuzumab (HuLuc63) in Phase I Study of Elotuzumab (HuLuc63) in Relapsed/Refractory Multiple Myeloma

Jeffrey A. Zonder, MD
Karmanos Cancer Institute
Detroit, Michigan

	12.27.08
To view the video full screen, click on the small button next to the volume control in the lower right hand corner. Be the first to comment	print share \| related articles